![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Glasgow: First Prospective Comparison of Genotypic vs Phenotypic Tropism Assays in Predicting Virologic Responses to Maraviroc (MVC) in a Phase 3 Study: MODERN
|
|
|
Reported by Jules Levin
HIV Drug Therapy Glasgow; November 2-6, 2014; Glasgow, UK
J Heera,1SR Valluri,2C Craig,3A Fang,2N Thomas,1RD Meyer,1J Demarest4
1Pfizer Inc, Groton, CT, USA; 2Pfizer Inc, New York, NY, USA; 3Pfizer Inc, Sandwich, Kent, UK; 4ViiV Healthcare, Research Triangle Park, NC, USA
![Glasgow1.gif](../images/110614/110614-3/Glasgow1.gif)
![Glasgow2.gif](../images/110614/110614-3/Glasgow2.gif)
![Glasgow3.gif](../images/110614/110614-3/Glasgow3.gif)
![Glasgow4.gif](../images/110614/110614-3/Glasgow4.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|